Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9693100 | 0.93 | LTA4H (0.53) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL9341171 | 0.86 | LTA4H (0.53) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL1379752 | 0.81 | LTA4H (0.57) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL8208882 | 0.80 | CYP1A2 (0.54) | SMN1; SMN2LMNAKIF11CYP3A4TSHR | |
| SCHEMBL17964411 | 0.80 | LTA4H (0.55) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL29832496 | 0.80 | KIF11 (0.50) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL29271946 | 0.79 | KIF11 (0.45) | SMN1; SMN2HTTLMNAKMT2AKIF11 | |
| SCHEMBL9693119 | 0.79 | LTA4H (0.50) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL8592603 | 0.79 | LTA4H (0.53) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA | |
| SCHEMBL11374176 | 0.79 | LTA4H (0.53) | LTA4HSIGMAR1SMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
| EP-1622572-B1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3231445-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3222294-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2415486-B1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8461313-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-4110368-A | PROSTAGLANDINS, BRONCHODILATOR, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4082736-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4076947-A | BRONCHODILATORS, HYPOTENSIVE AGENTS, ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4012448-A | Synthesis of adriamycin and 7,9-epiadriamycin | STANFORD RESEARCH INSTITUTE (US) | 1977-03-15 | — | — | US | disclosed |
| US-4007210-A | PROSTANOIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-3993674-A | ANTIULCER, BRONCHODILATOR, HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3966773-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3932479-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LTA4H 3053/4885SIGMAR1 3387/4885SMN1; SMN2 2517/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | LTA4H 3053/4885SIGMAR1 3387/4885SMN1; SMN2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.